EICHORPublic-registry site landscape for NCT01785771, “A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c”, a Type 2 Diabetes study sponsored by Intarcia Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01785771 (registry record) |
| Study title | A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c |
| Official title | An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c |
| Sponsor | Intarcia Therapeutics |
| Condition(s) | Type 2 Diabetes |
| Phase | PHASE3 |
| Listed sites | 51 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT01785771.
Eichor generates a preliminary site-risk snapshot for NCT01785771 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Type 2 Diabetes trials
More from Intarcia Therapeutics
← Eichor home · All tracked trials · Type 2 Diabetes studies · Weekly briefs
